Sort by
Keyphrases
Phase I Clinical Trial
100%
Riluzole
100%
Bevacizumab
100%
Metastatic Colorectal Cancer (mCRC)
100%
MFOLFOX6
100%
Twice Daily
33%
FOLFOX
33%
Dose Escalation
22%
CD8+ T Cells
22%
Stable Disease
22%
Duration of Response
22%
Disease Control Rate
22%
Objective Response Rate
22%
Patient-completed
11%
Response Rate
11%
Tumor Growth
11%
Adverse Events
11%
Neutropenia
11%
Amyotrophic Lateral Sclerosis
11%
Abdominal Pain
11%
Maximum Tolerated Dose
11%
Standard of Care
11%
Chemotherapy
11%
Colorectal Cancer
11%
Cancer Mortality
11%
2-cycles
11%
Syngeneic
11%
Immunomodulatory Effect
11%
Poor Performance Status
11%
Complete Response
11%
Partial Response
11%
Targeted Agents
11%
Colon Cancer
11%
Progressive Disease
11%
IFN Signaling
11%
Mouse Tumor Model
11%
Once-daily
11%
Cancer Causes
11%
Tumor Inhibition
11%
Disease Resistance
11%
New Treatment Options
11%
Clinical Activity
11%
Lymphopenia
11%
Fluoropyrimidine-based Chemotherapy
11%
Locally Advanced Disease
11%
Microsatellite Stable
11%
Phase I Trial
11%
Immune Checkpoint Blockade
11%
CGAS-STING
11%
Clinical Trial Information
11%
Oral Medicine
11%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Bevacizumab
100%
Metastatic Colorectal Cancer
100%
Riluzole
100%
Diseases
77%
Chemotherapy
22%
CD8 Antigen
22%
Tumor Growth
11%
Malignant Neoplasm
11%
Neutropenia
11%
Adverse Event
11%
Abdominal Pain
11%
Mouse Model
11%
Maximum Tolerated Dose
11%
Colon Carcinoma
11%
Preclinical Study
11%
Cancer Inhibition
11%
Amyotrophic Lateral Sclerosis
11%
Fluorouracil
11%
Disease Resistance
11%
Colorectal Carcinoma
11%
Lymphocytopenia
11%
Phase I Trials
11%
Immunomodulation
11%
Immunology and Microbiology
Bevacizumab
100%
Colorectal Carcinoma
100%
Cytotoxic T-Cell
40%
Mouse Model
20%
Syngenic
20%
Colon
20%
Preclinical Study
20%
Growth Inhibition
20%
Arm
20%
Lymphocytopenia
20%
Immunomodulation
20%
Immune Checkpoint Blockade
20%
Maximum Tolerated Dose
20%